دورية أكاديمية
أعرض في EDS

The CXCL12 Crossroads in Cancer Stem Cells and Their Niche.

التفاصيل البيبلوغرافية
العنوان: The CXCL12 Crossroads in Cancer Stem Cells and Their Niche.
المؤلفون: López-Gil JC; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain.; Department of Biochemistry, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.; Chronic Diseases and Cancer, Area 3-Instituto Ramon y Cajal de Investigación Sanitaria (IRYCIS), 28029 Madrid, Spain., Martin-Hijano L; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain.; Department of Biochemistry, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.; Chronic Diseases and Cancer, Area 3-Instituto Ramon y Cajal de Investigación Sanitaria (IRYCIS), 28029 Madrid, Spain., Hermann PC; Department of Internal Medicine I, Ulm University, 89081 Ulm, Germany., Sainz B Jr; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain.; Department of Biochemistry, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.; Chronic Diseases and Cancer, Area 3-Instituto Ramon y Cajal de Investigación Sanitaria (IRYCIS), 28029 Madrid, Spain.
المصدر: Cancers [Cancers (Basel)] 2021 Jan 26; Vol. 13 (3). Date of Electronic Publication: 2021 Jan 26.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Cancer stem cells (CSCs) are defined as a subpopulation of "stem"-like cells within the tumor with unique characteristics that allow them to maintain tumor growth, escape standard anti-tumor therapies and drive subsequent repopulation of the tumor. This is the result of their intrinsic "stem"-like features and the strong driving influence of the CSC niche, a subcompartment within the tumor microenvironment that includes a diverse group of cells focused on maintaining and supporting the CSC. CXCL12 is a chemokine that plays a crucial role in hematopoietic stem cell support and has been extensively reported to be involved in several cancer-related processes. In this review, we will provide the latest evidence about the interactions between CSC niche-derived CXCL12 and its receptors-CXCR4 and CXCR7-present on CSC populations across different tumor entities. The interactions facilitated by CXCL12/CXCR4/CXCR7 axes seem to be strongly linked to CSC "stem"-like features, tumor progression, and metastasis promotion. Altogether, this suggests a role for CXCL12 and its receptors in the maintenance of CSCs and the components of their niche. Moreover, we will also provide an update of the therapeutic options being currently tested to disrupt the CXCL12 axes in order to target, directly or indirectly, the CSC subpopulation.
References: PLoS One. 2011;6(9):e24605. (PMID: 21957456)
J Surg Oncol. 2011 Aug 1;104(2):140-5. (PMID: 21520098)
BMC Cancer. 2019 Feb 13;19(1):148. (PMID: 30760238)
Nature. 2011 Oct 19;478(7369):399-403. (PMID: 22012397)
Cancer Res. 2012 Jun 1;72(11):2768-79. (PMID: 22472119)
J Exp Med. 2006 Sep 4;203(9):2201-13. (PMID: 16940167)
Oncogene. 2019 Jun;38(25):5021-5037. (PMID: 30874597)
Cell. 2008 May 16;133(4):704-15. (PMID: 18485877)
Oncogene. 2016 Feb 11;35(6):671-82. (PMID: 25961921)
Cancer Res. 2006 Jan 15;66(2):1123-31. (PMID: 16424049)
Blood. 2011 Oct 20;118(16):4431-9. (PMID: 21868571)
Expert Rev Mol Med. 2015 Jan 30;17:e3. (PMID: 25634527)
Clin Cancer Res. 2011 Apr 15;17(8):2074-80. (PMID: 21349998)
Neuro Oncol. 2012 Nov;14(11):1379-92. (PMID: 22965162)
Oncogene. 2017 Sep 28;36(39):5532-5543. (PMID: 28581520)
Cell Stem Cell. 2014 Mar 6;14(3):342-56. (PMID: 24607406)
Stem Cell Res Ther. 2018 Feb 12;9(1):34. (PMID: 29433559)
Nat Commun. 2018 Nov 30;9(1):5108. (PMID: 30504836)
Stem Cells Dev. 2015 Jul 15;24(14):1635-47. (PMID: 25867197)
BMC Cancer. 2015 Aug 01;15:569. (PMID: 26231656)
Science. 1993 Jul 30;261(5121):600-3. (PMID: 8342023)
J Cell Mol Med. 2008 Apr;12(2):374-90. (PMID: 18182063)
Nature. 2013 Sep 19;501(7467):346-54. (PMID: 24048067)
Cell. 2010 Apr 2;141(1):39-51. (PMID: 20371344)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Oncogene. 2016 Apr 21;35(16):2123-32. (PMID: 26212008)
Sci Rep. 2017 Oct 13;7(1):13162. (PMID: 29030596)
Int Rev Immunol. 2019;38(6):267-283. (PMID: 31578892)
J Mol Neurosci. 2017 Oct;63(2):152-158. (PMID: 28856557)
Gut. 2015 Dec;64(12):1921-35. (PMID: 25841238)
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10455-10460. (PMID: 28900008)
Cancer Res. 2009 Sep 15;69(18):7243-51. (PMID: 19738068)
Cancer Cell. 2011 Sep 13;20(3):370-83. (PMID: 21907927)
Oncogene. 2013 Jan 10;32(2):209-21. (PMID: 22370645)
Cell Rep. 2015 May 5;11(5):737-47. (PMID: 25921529)
Cell Rep. 2018 May 1;23(5):1239-1248. (PMID: 29719241)
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. (PMID: 24277834)
Mol Cells. 2019 Jul 31;42(7):530-545. (PMID: 31362469)
J Pathol. 2012 Jul;227(3):325-35. (PMID: 22262369)
J Clin Oncol. 2011 Feb 10;29(5):591-9. (PMID: 21220598)
Nature. 2020 Jan;577(7791):566-571. (PMID: 31915377)
Cancer Discov. 2012 Sep;2(9):840-55. (PMID: 22763855)
Oncotarget. 2017 May 30;8(22):36137-36148. (PMID: 28410224)
Exp Cell Res. 2018 Apr 1;365(1):12-23. (PMID: 29453972)
Cancer Lett. 2016 Oct 1;380(2):561-7. (PMID: 25979233)
Immunol Lett. 2019 Apr;208:19-29. (PMID: 30862442)
Cancer Cell. 2010 Feb 17;17(2):135-47. (PMID: 20138012)
Tumour Biol. 2016 Oct;37(10):13425-13433. (PMID: 27460092)
Cancer Res. 2014 Dec 15;74(24):7309-20. (PMID: 25368022)
Tumour Biol. 2016 Jul;37(7):8515-28. (PMID: 27079871)
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. (PMID: 19805294)
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8. (PMID: 14595012)
Blood. 2008 Apr 15;111(8):4233-44. (PMID: 18272812)
Oncotarget. 2016 Jun 28;7(26):39363-39375. (PMID: 27276704)
Nat Med. 2020 Feb;26(2):259-269. (PMID: 32042191)
Stem Cells Transl Med. 2017 Jun;6(6):1445-1451. (PMID: 28452204)
Int J Cancer. 2010 Mar 15;126(6):1302-15. (PMID: 19821487)
Am J Hematol. 2016 May;91(5):507-17. (PMID: 26822317)
J Stem Cells. 2010;5(2):75-81. (PMID: 22049617)
Oncotarget. 2012 Dec;3(12):1497-8. (PMID: 23455077)
Stem Cell Res Ther. 2018 Nov 9;9(1):310. (PMID: 30413179)
Cancer Immunol Immunother. 2016 Feb;65(2):161-9. (PMID: 26728481)
Cancer Biol Ther. 2009 Sep;8(17):1608-14. (PMID: 19625779)
Haematologica. 2010 May;95(5):776-84. (PMID: 20015878)
PLoS One. 2015 May 04;10(5):e0125625. (PMID: 25938772)
Oncotarget. 2017 May 30;8(22):36149-36160. (PMID: 28193907)
Mol Cancer. 2013 Jul 31;12(1):85. (PMID: 23902739)
Oncol Rep. 2013 Jun;29(6):2325-31. (PMID: 23563306)
Mediators Inflamm. 2016;2016:9012369. (PMID: 26980947)
Cell. 2018 Feb 8;172(4):841-856.e16. (PMID: 29395328)
Cell Mol Immunol. 2018 Apr;15(4):299-311. (PMID: 29082918)
Nature. 2017 Mar 29;543(7647):676-680. (PMID: 28358093)
Tumour Biol. 2017 Jun;39(6):1010428317695528. (PMID: 28639900)
Histopathology. 2009 May;54(6):741-50. (PMID: 19438749)
Mol Cancer. 2010 Oct 14;9:273. (PMID: 20946648)
Stem Cells. 2007 Nov;25(11):2739-49. (PMID: 17656645)
Cell Death Dis. 2017 Jan 19;8(1):e2560. (PMID: 28102846)
J Theor Biol. 2015 Jan 7;364:40-8. (PMID: 25195001)
Oncogene. 2006 Aug 17;25(36):4986-97. (PMID: 16568088)
Br Med J. 1881 Aug 6;2(1075):198-203. (PMID: 20749954)
Nat Med. 2007 May;13(5):587-96. (PMID: 17435771)
Biochem Biophys Res Commun. 2013 Mar 8;432(2):333-8. (PMID: 23396061)
J Exp Med. 2003 Nov 3;198(9):1391-402. (PMID: 14597738)
Nature. 2014 Jan 16;505(7483):327-34. (PMID: 24429631)
Nature. 2006 Jun 29;441(7097):1075-9. (PMID: 16810242)
Pancreas. 2015 May;44(4):528-34. (PMID: 25872129)
Sci Rep. 2016 Dec 20;6:39541. (PMID: 27996037)
Int J Biochem Cell Biol. 2019 Apr;109:90-104. (PMID: 30743057)
Nat Rev Immunol. 2003 Jan;3(1):23-35. (PMID: 12511873)
Cancer Cell. 2007 Jan;11(1):69-82. (PMID: 17222791)
Cancer Cell. 2017 Jan 9;31(1):110-126. (PMID: 27989801)
Cancer Res. 2008 Jun 1;68(11):4331-9. (PMID: 18519693)
Sci Rep. 2015 May 28;5:10357. (PMID: 26020117)
ACS Nano. 2017 Sep 26;11(9):8690-8706. (PMID: 28809532)
Nat Cell Biol. 2013 May;15(5):533-43. (PMID: 23624405)
Leukemia. 2006 Nov;20(11):1915-24. (PMID: 16900209)
Nat Med. 2020 Jun;26(6):878-885. (PMID: 32451495)
J Immunol. 2009 Mar 15;182(6):3530-9. (PMID: 19265131)
Cell Stem Cell. 2020 Apr 2;26(4):569-578.e7. (PMID: 32169167)
Cancer Res. 2010 Dec 15;70(24):10411-21. (PMID: 21056990)
Nat Rev Mol Cell Biol. 2019 May;20(5):303-320. (PMID: 30745579)
Lab Invest. 2012 Jan;92(1):151-62. (PMID: 21894147)
Korean J Intern Med. 2017 Jul;32(4):589-599. (PMID: 28704917)
Cancer Cell. 2018 Mar 12;33(3):463-479.e10. (PMID: 29455927)
J Biol Chem. 2011 Sep 16;286(37):32188-97. (PMID: 21730065)
Cancer Transl Med. 2017;3(3):87-95. (PMID: 29276782)
Nat Cell Biol. 2010 May;12(5):468-76. (PMID: 20418870)
Oncol Rep. 2017 Feb;37(2):921-928. (PMID: 27922681)
Oncol Rep. 2013 Feb;29(2):579-84. (PMID: 23232503)
FASEB J. 2015 Aug;29(8):3571-81. (PMID: 25962655)
Blood. 2000 Oct 15;96(8):2655-63. (PMID: 11023495)
Nat Rev Cancer. 2019 Dec;19(12):716-732. (PMID: 31666716)
Korean J Intern Med. 2017 Mar;32(2):248-257. (PMID: 28219003)
Front Immunol. 2019 Dec 13;10:2895. (PMID: 31921156)
Immunity. 2016 Dec 20;45(6):1219-1231. (PMID: 27913094)
Nat Rev Cancer. 2002 Oct;2(10):795-803. (PMID: 12360282)
Mol Cancer. 2015 Aug 19;14:157. (PMID: 26282129)
J Immunol. 2014 Nov 15;193(10):5327-37. (PMID: 25320277)
Mol Cell Biochem. 2011 Sep;355(1-2):241-8. (PMID: 21553023)
Biochim Biophys Acta Mol Cell Res. 2017 Mar;1864(3):594-603. (PMID: 28040478)
Nat Rev Mol Cell Biol. 2011 Feb;12(2):126-31. (PMID: 21253000)
Semin Cancer Biol. 2020 Oct;65:176-188. (PMID: 31874281)
Nature. 1996 Aug 29;382(6594):833-5. (PMID: 8752281)
Oncotarget. 2013 May;4(5):792-801. (PMID: 23801022)
J Exp Clin Cancer Res. 2019 Aug 5;38(1):339. (PMID: 31382985)
Front Immunol. 2020 Feb 05;11:140. (PMID: 32117287)
J Immunol. 2015 Oct 15;195(8):4010-9. (PMID: 26363055)
Int J Oncol. 2017 Feb;50(2):505-514. (PMID: 28000861)
Cytotherapy. 2006;8(4):315-7. (PMID: 16923606)
Int J Oncol. 2016 Mar;48(3):1085-94. (PMID: 26782945)
Integr Biol (Camb). 2016 Dec 5;8(12):1246-1260. (PMID: 27775742)
Cytokine Growth Factor Rev. 2018 Dec;44:51-68. (PMID: 30396776)
Semin Cancer Biol. 2018 Dec;53:223-231. (PMID: 30130664)
Cancer Res. 2015 Sep 1;75(17):3529-42. (PMID: 26330165)
Mol Cancer Ther. 2014 Jul;13(7):1758-71. (PMID: 24785258)
Oncogene. 2019 Jul;38(27):5469-5485. (PMID: 30936462)
Lab Invest. 2016 May;96(5):517-25. (PMID: 26878134)
Hepatology. 2015 Oct;62(4):1160-73. (PMID: 26154152)
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2305-9. (PMID: 8134392)
Mol Cancer. 2017 Feb 1;16(1):28. (PMID: 28148265)
Eur J Cancer. 2010 May;46(7):1271-7. (PMID: 20303742)
Oncogene. 2015 Jan 15;34(3):290-302. (PMID: 24441045)
Sci Rep. 2017 Oct 23;7(1):13856. (PMID: 29062075)
Trends Cancer. 2019 Nov;5(11):724-741. (PMID: 31735290)
Nat Rev Cancer. 2013 Oct;13(10):739-52. (PMID: 24060865)
Integr Biol (Camb). 2016 Feb;8(2):167-76. (PMID: 26762753)
Stem Cells Transl Med. 2017 Dec;6(12):2115-2125. (PMID: 29072369)
Oncogene. 2018 Apr;37(15):1961-1975. (PMID: 29367761)
Brain Tumor Pathol. 2019 Apr;36(2):63-73. (PMID: 30968276)
Cell Stem Cell. 2007 Sep 13;1(3):313-23. (PMID: 18371365)
Front Oncol. 2020 Feb 07;10:109. (PMID: 32117758)
Cancer Res. 2004 Jun 15;64(12):4302-8. (PMID: 15205345)
Nature. 2019 Aug;572(7768):254-259. (PMID: 31316209)
Mol Cancer. 2019 Apr 13;18(1):88. (PMID: 30979371)
Front Oncol. 2019 Jul 31;9:688. (PMID: 31417869)
Sci Rep. 2016 Feb 19;6:21420. (PMID: 26892992)
Cancer Lett. 2016 Oct 1;380(2):545-51. (PMID: 25527451)
Mol Vis. 2012;18:588-92. (PMID: 22419851)
Nature. 1996 Aug 15;382(6592):635-8. (PMID: 8757135)
Nat Rev Cancer. 2016 Aug 23;16(9):582-98. (PMID: 27550820)
Cancer Lett. 2016 Jun 28;376(1):137-47. (PMID: 27033454)
Med Sci Monit. 2018 Jul 26;24:5185-5191. (PMID: 30047547)
Nature. 1994 Feb 17;367(6464):645-8. (PMID: 7509044)
Cancer Sci. 2016 Jan;107(1):12-7. (PMID: 26440127)
Cancer Cell. 2019 Apr 15;35(4):588-602.e10. (PMID: 30930117)
Front Immunol. 2019 Feb 08;10:168. (PMID: 30800125)
Mol Biol Rep. 2019 Dec;46(6):6629-6645. (PMID: 31486978)
J Leukoc Biol. 2016 Jun;99(6):863-8. (PMID: 26965637)
Blood. 2012 Mar 15;119(11):2556-67. (PMID: 22289889)
Oncogene. 2018 Feb 15;37(7):873-883. (PMID: 29059160)
Br J Cancer. 2012 Mar 27;106(7):1306-13. (PMID: 22415233)
Int J Cancer. 2019 Aug 15;145(4):1099-1110. (PMID: 30671927)
Cell Stem Cell. 2015 Mar 5;16(3):225-38. (PMID: 25748930)
Semin Cancer Biol. 2018 Dec;53:189-200. (PMID: 30261276)
Oncotarget. 2016 Dec 6;7(49):81144-81155. (PMID: 27835894)
Blood. 2020 Dec 24;136(26):2994-3003. (PMID: 32870250)
Sci Rep. 2016 Mar 15;6:22793. (PMID: 26976451)
Clin Cancer Res. 2014 Feb 1;20(3):604-16. (PMID: 24255072)
Int J Clin Exp Pathol. 2015 Oct 01;8(10):12357-67. (PMID: 26722422)
J Cancer Res Clin Oncol. 2017 Jan;143(1):95-104. (PMID: 27638770)
PLoS One. 2011;6(12):e29461. (PMID: 22220212)
Cell Stem Cell. 2019 May 2;24(5):769-784.e6. (PMID: 30905620)
Nat Commun. 2014 Mar 25;5:3472. (PMID: 24668028)
J Transl Med. 2011 Dec 16;9:216. (PMID: 22176642)
Cancers (Basel). 2019 May 02;11(5):. (PMID: 31052565)
Oncogenesis. 2018 Oct 5;7(10):78. (PMID: 30287850)
Neuro Oncol. 2015 Jan;17(1):81-94. (PMID: 25085362)
Nat Immunol. 2018 Feb;19(2):108-119. (PMID: 29348500)
Nature. 2017 May 11;545(7653):187-192. (PMID: 28355176)
Oncol Lett. 2018 Jan;15(1):453-458. (PMID: 29422961)
Cell Stem Cell. 2015 Aug 6;17(2):152-164. (PMID: 26212080)
Immunity. 2010 Sep 24;33(3):387-99. (PMID: 20850355)
Front Physiol. 2014 Jun 11;5:212. (PMID: 24966838)
Int Immunopharmacol. 2019 Oct;75:105818. (PMID: 31437795)
Cancer Res. 2015 Sep 1;75(17):3636-49. (PMID: 26141860)
J Histochem Cytochem. 2018 Mar;66(3):155-173. (PMID: 29297738)
J Endocrinol Invest. 2008 Sep;31(9):809-19. (PMID: 18997494)
Oncogene. 2016 Feb 18;35(7):816-26. (PMID: 25961926)
Nature. 2011 Dec 07;481(7379):85-9. (PMID: 22158103)
Biochem Biophys Res Commun. 2018 Oct 28;505(2):593-599. (PMID: 30274780)
PLoS One. 2010 Apr 26;5(4):e10088. (PMID: 20436665)
Inflamm Res. 2020 Feb;69(2):167-178. (PMID: 31865399)
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352. (PMID: 32300252)
Cancers (Basel). 2018 Jan 26;10(2):. (PMID: 29373514)
Oncotarget. 2016 Feb 9;7(6):6916-32. (PMID: 26755648)
J Cancer Res Clin Oncol. 2009 Jan;135(1):91-102. (PMID: 18670789)
Int J Cancer. 1997 Nov 27;73(5):656-62. (PMID: 9398042)
Nature. 2011 Sep 18;478(7368):255-9. (PMID: 21927002)
J Exp Med. 2006 Jul 10;203(7):1701-11. (PMID: 16818678)
Cancer Cell. 2015 Dec 14;28(6):800-814. (PMID: 26585400)
Cell. 2013 Jan 17;152(1-2):25-38. (PMID: 23273993)
Cancer Immunol Immunother. 2017 Aug;66(8):1025-1036. (PMID: 28401258)
Front Immunol. 2018 Mar 12;9:476. (PMID: 29662484)
Nature. 1996 Aug 29;382(6594):829-33. (PMID: 8752280)
PLoS One. 2018 Jun 19;13(6):e0198789. (PMID: 29920526)
Cancer Res. 2011 Jan 15;71(2):614-24. (PMID: 21224357)
Anticancer Res. 2015 Jan;35(1):53-64. (PMID: 25550535)
Neuro Oncol. 2017 Jan;19(1):66-77. (PMID: 27370398)
Protein Cell. 2011 Apr;2(4):266-72. (PMID: 21533771)
Clin Cancer Res. 2016 Nov 15;22(22):5592-5604. (PMID: 27267855)
PLoS One. 2015 Jun 25;10(6):e0130808. (PMID: 26110809)
PLoS One. 2016 Oct 25;11(10):e0164514. (PMID: 27780254)
Cell Stem Cell. 2013 Sep 5;13(3):285-99. (PMID: 23850243)
J Biol Chem. 2008 Feb 15;283(7):4283-94. (PMID: 18057003)
Oncogene. 2014 May 22;33(21):2768-78. (PMID: 23792449)
Stem Cell Res. 2016 Mar;16(2):349-57. (PMID: 26896855)
Int J Clin Exp Pathol. 2015 Oct 01;8(10):13217-24. (PMID: 26722521)
J Pathol. 2011 Jul;224(3):344-54. (PMID: 21618540)
Gene. 2018 Jan 30;641:105-110. (PMID: 29017963)
J Histochem Cytochem. 2015 Jul;63(7):481-93. (PMID: 25809793)
Nat Med. 2011 Jun 26;17(7):867-74. (PMID: 21706029)
Front Immunol. 2014 Jul 29;5:360. (PMID: 25120546)
EMBO Rep. 2014 Dec;15(12):1243-53. (PMID: 25381661)
Clin Cancer Res. 2017 Mar 1;23(5):1250-1262. (PMID: 27542769)
Curr Opin Hematol. 2008 Jan;15(1):49-58. (PMID: 18043246)
J Neurooncol. 2014 Mar;117(1):43-51. (PMID: 24442483)
Trends Mol Med. 2007 Feb;13(2):72-81. (PMID: 17197241)
Oncotarget. 2014 Nov 30;5(22):11283-96. (PMID: 25526031)
Crit Rev Oncol Hematol. 2018 May;125:102-110. (PMID: 29650269)
Transfus Med Hemother. 2013 Aug;40(4):237-45. (PMID: 24179472)
Cancer Res. 2004 Apr 15;64(8):2817-24. (PMID: 15087398)
Immunity. 2006 Dec;25(6):977-88. (PMID: 17174120)
Cell Stem Cell. 2011 Nov 4;9(5):433-46. (PMID: 22056140)
Cell Stem Cell. 2014 Dec 4;15(6):762-74. (PMID: 25515522)
Int J Mol Sci. 2019 Sep 27;20(19):. (PMID: 31569731)
Mol Cancer. 2010 Nov 18;9:295. (PMID: 21087507)
معلومات مُعتمدة: GC16173694BARB Fundación Científica Asociación Española Contra el Cáncer; n/a Fundación Fero; Max Eder Fellowship 111746 Deutsche Krebshilfe; 316249678 - SFB 1279 Deutsche Stiftung Friedensforschung; M65.1 Hector Foundation Cancer Research grant
فهرسة مساهمة: Keywords: CSC niche; CXCL12; CXCR4; CXCR4 inhibitors; cancer stem cells
تواريخ الأحداث: Date Created: 20210203 Latest Revision: 20210210
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7866198
DOI: 10.3390/cancers13030469
PMID: 33530455
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13030469